In a recent pilot study published in the journal Digital Health a team of researchers are testing new technologies for Parkinson’s disease (PD) which may influence clinical research in personal genetic testing to better diagnose and potentially treat PD. “These findings demonstrate that remote recruitment and conduct…
Amarantus BioScience Holdings, Inc., a biotechnology company focused on advancing therapeutic and diagnostic products for orphan and neurologic diseases, recently announced they have dosed the first patient in a Phase 2b clinical trial of flagship neurology pipeline drug eltoprazine, indicated as a potential treatment for Parkinson’s disease levodopa-induced dyskinesia (PD-LID).
In a new study entitled “Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease” an international team of scientists discovered that anti-malaria drugs chloroquine and amodiaquine are potential therapeutics for Parkinson’s disease. The study was published in…
Symptoms associated with Parkinson’s disease include tremor, muscle stiffness, and slowed movement that make it difficult to execute such simple tasks as holding an eating utensil steady, and patients currently have few options for relief outside of a hospital or clinic. Some medications can help, but over time they tend…
Geneticist Haydeh Payami, PhD., has made it her life’s mission to prevent parkinson’s disease (PD) in individuals who are genetically prone to the debilitating condition, and to devise effective personalized treatments for people who already have the disease. To achieve these lofty goals, Dr. Payami, who earned a PhD…
Deciphering the complex connections and neural networks of the brain is a herculean task. The brain is made of grey and white matter – the former consisting of neuronal cell bodies associated with receipt of sensory information from all major organs of the body aiding in vital processes like muscle…
Plans for a new research venture is in the works in the North-West of England through the joint efforts of the Association for the Independence of Disabled People (AID) and medical researchers at Lancaster University. AID was founded by Mr. Paul and the Hon. Mrs. Ruth Adorian of Windermere, following Ruth’s own…
In a new study entitled “Dopaminergic Modulation of Decision Making and Subjective Well-Being”, published in the Journal of Neuroscience, researchers show that decisions on risk-taking may be influenced by a boost in the levels of the neurotransmitter dopamine. These findings are in line with previous reports that…
Progressive loss of neurons in the brains of Parkinson’s patients is a slow yet inexorable process, and so far, there are no drugs that can halt this insidious process. However, teams of researchers at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have now…
Researchers at the University of Alabama at Birmingham (UAB) and Pfizer Inc. recently reported encouraging findings on a new inhibitor drug that can reduce neurodegeneration in animal models of Parkinson’s disease. The study was published in The Journal of Biological Chemistry and is entitled “…
Get regular updates to your inbox.
